Overview
Trojan horse delivers therapeutic cargos by binding to specific receptor located on over 400 miles of capillaries throughout our brain:
- Facilitated transport: Fast delivery to the brain following IV administration.
- Uniform distribution to all brain regions .
- Low dose (less toxicity and immunogenicity potential).
Technology can deliver diverse cargos:
- Flexible Attachment Modes: Covalent or Electrostatic.
- IV delivery of gene-silencing therapeutics (siRNA, ASO), peptides, and proteins into the brain.
Patents:
- Five issued patents in the US, three in Japan, one in France, Germany and UK.
- Seven additional patents are currently being prosecuted.
The non-invasive Ophidion IV platform efficiently delivers therapeutics to the brain using low doses for fast and extensive brain penetration